

Table 4 Summary of pharmacokinetic parameters

Analyte	Patient	Combination	C_{max} , ng/ml	AUC, ng h/ml
Arm A				
Cediranib	Patient 1	Cediranib alone	25.5	378
		Cediranib + S-1 + cisplatin	51.3	598
	Patient 2	Cediranib alone	153	2,640
		Cediranib + S-1 + cisplatin	192	2,780
5-FU	Patient 1 (60 mg S-1)	S-1 + cisplatin	58.6	302
		Cediranib + S-1 + cisplatin	92.1	446
		S-1 + cisplatin	182	908
	Patient 2 (50 mg S-1)	S-1 + cisplatin	130	644
		Cediranib + S-1 + cisplatin	2,740	12,700
		S-1 + cisplatin	2,400	10,400
Cisplatin	Patient 1	S-1 + cisplatin	3,040	14,100
		Cediranib + S-1 + cisplatin	2,790	12,600
		S-1 + cisplatin	2,400	10,400
	Patient 2	S-1 + cisplatin	2,400	10,400
		Cediranib + S-1 + cisplatin	2,790	12,600
		S-1 + cisplatin	2,400	10,400
Arm B				
Cediranib	All patients ($n = 4$)	Cediranib alone	77.5 (32.9–99.9)	1,180 (479–1,800)
	All patients ($n = 4$)	Cediranib + capecitabine + cisplatin	86.3 (50.2–115)	1,220 (687–1,850)
5-FU	Patient 3 (1,600 mg capecitabine)	Capecitabine + cisplatin	130	283
		Cediranib + capecitabine + cisplatin	284	421
	Patient 4 (1,750 mg capecitabine)	Capecitabine + cisplatin	132	187
		Cediranib + capecitabine + cisplatin	983	889
	Patient 5 (1,450 mg capecitabine)	Capecitabine + cisplatin	167	305
		Cediranib + capecitabine + cisplatin	105 ^a	335 ^a
Patient 6 (1,600 mg capecitabine)	Capecitabine + cisplatin	287	518	
	Cediranib + capecitabine + cisplatin	392 ^b	647 ^b	
Cisplatin	All patients ($n = 4$)	Capecitabine + cisplatin	3,430 (2,720–3,840)	16,900 (13,500–18,900)
	All patients ($n = 4$)	Cediranib + capecitabine + cisplatin	4,620 (3,230–5,720)	21,700 (16,600–23,600)

AUC_{0–24h} was calculated for cediranib; AUC_{0–4h} for capecitabine (5-FU); and AUC_{0–8h} for cisplatin and S-1 (5-FU)

In Arm B, cediranib and cisplatin parameters are expressed as mean (min–max); all other data are individual patient values as there are insufficient data to summarize by mean value

AUC area under the plasma concentration–time curve, C_{max} maximum plasma (peak) drug concentration

^a Dose of 1,300 mg capecitabine administered: data dose normalized to 1,450 mg

^b Dose of 1,200 mg capecitabine administered: data dose normalized to 1,600 mg


Discussion

The impact of conventional chemotherapy on advanced gastric cancer remains modest, with median survival times reaching a plateau of 7–13 months [6–8]. More effective treatment options are needed. In this Phase I study, we evaluated the VEGF signalling inhibitor cediranib in combination with cisplatin and S-1 or capecitabine in Japanese patients with previously untreated locally advanced or metastatic unresectable gastric adenocarcinoma. Treatment was tolerable, with only one patient in each arm experiencing a DLT. Overall, the safety profile of each regimen was consistent with previous studies of the individual agents in patients with advanced cancer [8, 9, 18, 19, 23, 28–30], and no new toxicities were identified. The most commonly reported AEs were decreased

appetite, fatigue and nausea. There were no reports of severe hypertension as a SAE, and the overall incidence of hypertension was consistent with that reported in a Phase I study of cediranib monotherapy in Japanese patients [18].

Insufficient PK data preclude any meaningful conclusions relating to Arm A. Based on the limited PK data from Arm B, there was no clear indication of a consistent interaction between cediranib and cisplatin/capecitabine. This is not unexpected as it is considered unlikely that cisplatin, capecitabine or S-1 would affect cediranib routes of metabolism [31]. The slight increases in cisplatin exposure observed in all patients when cediranib was administered with chemotherapy compared to chemotherapy alone may be due to an accumulation of platinum following multiple dosing.

Fig. 2 Waterfall plot for best change in tumour size in each patient



In this small Phase I study, tumour shrinkage was observed in five of seven evaluable patients. This preliminary evidence of antitumour activity is consistent with the efficacy findings observed in an early-phase dose-finding study of sorafenib, a multi-targeted kinase inhibitor with activity versus VEGFR-2 and -3, in combination with capecitabine and cisplatin as a first-line treatment for patients with advanced gastric cancer [32]. However, targeting VEGF signalling with bevacizumab, an anti-VEGF-A monoclonal antibody, in patients with advanced gastric cancer met with disappointing results in the recently reported Phase III AVAGAST study [33]. This first-line study failed to meet its primary endpoint of improved overall survival with the addition of bevacizumab to cisplatin plus capecitabine/5-FU, although an efficacy analysis by geographical region revealed that, for both arms, median overall survival was greatest for patients who enrolled in the Asia/Pacific region. Despite the primary outcome of the AVAGAST study, the bevacizumab regimen showed significant advantages for the secondary efficacy endpoints of progression-free survival and overall response rate, suggesting that anti-VEGF treatment strategies are worthy of continued investigation in advanced gastric cancer.

In conclusion, cediranib 20 mg plus cisplatin and S-1 or capecitabine had a manageable tolerability profile as a first-line treatment in Japanese patients with advanced gastric cancer and showed preliminary evidence of antitumour activity.

Acknowledgments Funding for this study was provided by AstraZeneca. We thank Paul Williams, PhD, from Mudskipper Bioscience, who provided medical writing assistance funded by AstraZeneca.

Conflict of interest X.S. and K.H.B. are employees of AstraZeneca and own stock. T.S., Y.Y., K.M., H.H., Y.S., D.T., K.T., T.E.N. and N.B. declare no conflicts of interest.

References

1. GLOBOCAN statistics. 2008. Available at <http://globocan.iarc.fr/>
2. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M (1993) Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. *Cancer* 72:37–41
3. Glimelius B, Hoffman K, Haglund U, Nyren O, Sjoden PO (1994) Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. *Ann Oncol* 5:189–190
4. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M (1995) Randomised comparison of fluorouracil, epirubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. *Br J Cancer* 71: 587–591
5. Fujii M, Kochi M, Takayama T (2010) Recent advances in chemotherapy for advanced gastric cancer in Japan. *Surg Today* 40:295–300
6. Ohtsu A, Shimada Y, Yoshida S, Saito H, Seki S, Morise K, Kurihara M (1994) Phase II study of protracted infusional 5-fluorouracil combined with cisplatin for advanced gastric cancer: report from the Japan clinical oncology group (JCOG). *Eur J Cancer* 30A:2091–2093
7. Koizumi W, Kurihara M, Sasai T, Yoshida S, Morise K, Imamura A, Akazawa S, Betsuyaku T, Ohkubo S, Takahashi H et al (1993) A phase II study of combination therapy with 5'-deoxy-5-fluorouridine and cisplatin in the treatment of advanced gastric cancer with primary foci. *Cancer* 72:658–662
8. Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, Shirao K, Matsumura Y, Gotoh M (2003) Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. *Br J Cancer* 89:2207–2212

9. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. *Lancet Oncol* 9:215–221
10. Van Cutsem E, Kang Y, Chung H, Shen L, Sawaki A, Lordick F, Hill J, Lehle M, Feyereislova A, Bang Y (2009) Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). *J Clin Oncol* 27(18S):abst LBA4509
11. Ferrara N (2002) Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. *Semin Oncol* 29:10–14
12. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N Engl J Med* 350:2335–2342
13. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S (2005) Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. *J Clin Oncol* 23:3706–3712
14. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. *J Clin Oncol* 26:2013–2019
15. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilienbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. *N Engl J Med* 355:2542–2550
16. Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Wedge SR, Jürgensmeier JM (2007) Inhibition of VEGF-C-induced VEGFR-3 activity and lymphatic endothelial cell function by the tyrosine kinase inhibitor AZD2171. *Proc Am Assoc Cancer Res* 48:abst 2999
17. Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO, Chester R, Jackson JA, Boffey SJ, Kilburn LL, Barnett S, Richmond GH, Wadsworth PF, Walker M, Bigley AL, Taylor ST, Cooper L, Beck S, Jürgensmeier JM, Ogilvie DJ (2005) AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. *Cancer Res* 65:4389–4400
18. Yamamoto N, Tamura T, Yamamoto N, Yamada K, Yamada Y, Nokihara H, Fujiwara Y, Takahashi T, Murakami H, Boku N, Yamazaki K, Puchalski TA, Shin E (2009) Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors. *Cancer Chemother Pharmacol* 64:1165–1172
19. Drevs J, Siegert P, Medinger M, Mross K, Strecker R, Zirrgiebel U, Harder J, Blum H, Robertson J, Jürgensmeier JM, Puchalski TA, Young H, Saunders O, Unger C (2007) Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. *J Clin Oncol* 25:3045–3054
20. Laurie SA, Gauthier I, Arnold A, Shepherd FA, Ellis PM, Chen E, Goss G, Powers J, Walsh W, Tu D, Robertson J, Puchalski TA, Seymour L (2008) Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. *J Clin Oncol* 26:1871–1878
21. Chen E, Jonker D, Gauthier I, Maclean M, Wells J, Powers J, Seymour L (2009) Phase I study of cediranib in combination with oxaliplatin and infusional 5-fluorouracil in patients with advanced colorectal cancer. *Clin Cancer Res* 15:1481–1486
22. Goss G, Shepherd FA, Laurie S, Gauthier I, Leigh N, Chen E, Feld R, Powers J, Seymour L (2009) A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group. *Eur J Cancer* 45:782–788
23. LoRusso P, Shields AF, Gadgeel S, Vaishampayan U, Guthrie T, Puchalski T, Xu J, Liu Q (2010) Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study. *Invest New Drugs*. doi:10.1007/s10637-010-9484-5. Epub ahead of print
24. Goss GD, Arnold A, Shepherd FA, Dediu M, Ciuleanu TE, Fenton D, Zukin M, Walde D, Laberge F, Vincent MD, Ellis PM, Laurie SA, Ding K, Frymire E, Gauthier I, Leigh NB, Ho C, Noble J, Lee CW, Seymour L (2010) Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. *J Clin Oncol* 28:49–55
25. Robertson JD, Botwood NA, Rothenberg ML, Schmoll H-J (2009) Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III. *Clin Colorectal Cancer* 8:59–60
26. AstraZeneca (2011) Global policy: bioethics. Available at <http://www.astrazeneca.com/Responsibility/Code-policies-standards/Policiesstandards>
27. Therasse P (2002) Measuring the clinical response. What does it mean? *Eur J Cancer* 38:1817–1823
28. vanCrujssen H, Voest EE, van Herpen CML, Hoekman K, Witteveen PO, Tjin-A-Ton ML, Punt CJ, Puchalski T, Milenkova T, Giaccone G (2006) Phase I evaluation of AZD2171, a highly potent, selective VEGFR signaling inhibitor, in combination with gefitinib, in patients with advanced tumors. *J Clin Oncol* 24(S18):abst 3017
29. Lee SS, Lee JL, Ryu MH, Chang HM, Kim TW, Kang HJ, Kim WK, Lee JS, Kang YK (2007) Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis. *Jpn J Clin Oncol* 37:30–37
30. Lee JO, Lee KW, Oh DY, Kim JH, Im SA, Kim TY, Bang YJ (2009) Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma. *Ann Oncol* 20:1402–1407
31. Schulz-Utermoehl T, Spear M, Pollard CR, Pattison C, Rollison H, Sarda S, Ward M, Bushby N, Jordan A, Harrison M (2010) In vitro hepatic metabolism of cediranib, a potent vascular endothelial growth factor tyrosine kinase inhibitor: interspecies comparison and human enzymology. *Drug Metab Dispos* 38:1688–1697
32. Kim C, Lee J-L, Choi YH, Kang BW, Ryu M-H, Chang HM, Kim TW, Kang Y-K (2011) Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer. *Invest New Drugs*. doi:10.1007/s10637-010-9531-2. Epub ahead of print
33. Kang Y, Ohtsu A, Van Cutsem E, Rha SY, Sawaki A, Park P, Lim H, Wu J, Langer B, Shah MA (2010) AVAGAST: a randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). *J Clin Oncol* 28(18S):abst LBA4007

Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy

HK Kim^{1,2}, IJ Choi², CG Kim²,
HS Kim², A Oshima¹, Y Yamada³,
T Arao⁴, K Nishio⁴,
A Michalowski¹ and JE Green¹

¹Laboratory of Cancer Biology and Genetics, National Cancer Institute, Bethesda, MD, USA; ²National Cancer Center, Goyang, Gyeonggi, Republic of Korea, ³National Cancer Center, Tokyo, Japan and ⁴Kinki University School of Medicine, Osaka-Sayama, Japan

Correspondence:

Dr JE Green, Laboratory of Cancer Biology and Genetics, National Cancer Institute, 37 Convent Drive, Bethesda, MD 20892, USA.
E-mail: JEGreen@mail.nih.gov

To identify transcriptional profiles predictive of the clinical benefit of cisplatin and fluorouracil (CF) chemotherapy to gastric cancer patients, endoscopic biopsy samples from 96 CF-treated metastatic gastric cancer patients were prospectively collected before therapy and analyzed using high-throughput transcriptional profiling and array comparative genomic hybridization. Transcriptional profiling identified 917 genes that are correlated with poor patient survival after CF at $P < 0.05$ (poor prognosis signature), in which protein synthesis and DNA replication/recombination/repair functional categories are enriched. A survival risk predictor was then constructed using genes, which are included in the *poor prognosis signature* and are contained within identified genomic amplicons. The combined expression of three genes—*MYC*, *EGFR* and *FGFR2*—was an independent predictor for overall survival of 27 CF-treated patients in the validation set (adjusted $P = 0.017$), and also for survival of 40 chemotherapy-treated gastric cancer patients in a published data set (adjusted $P = 0.026$). Thus, combined expression of *MYC*, *EGFR* and *FGFR2* is predictive of poor survival in CF-treated metastatic gastric cancer patients.

The Pharmacogenomics Journal (2012) 12, 119–127; doi:10.1038/tpj.2010.87; published online 21 December 2010

Keywords: gastric; cancer; chemotherapy; gene; expression

Introduction

Although the emerging area of targeted anticancer agents holds great promise, cytotoxic chemotherapy remains the primary treatment option for many cancer patients. Identifying patients who likely will or will not benefit from cytotoxic chemotherapy through the use of biomarkers could greatly improve clinical management by better defining appropriate treatment options for patients. None of the molecules experimentally identified to cause chemotherapy resistance *in vitro* was sufficiently validated in primary tumors and thus clinically applicable,¹ underscoring the importance of well-designed, clinical study to identify clinically relevant mechanisms for chemotherapy resistance. In fact, however, such predictors derived to date from high-throughput transcriptional profiling of primary tumors, especially gastrointestinal tract cancers, have not shown satisfactory performance.^{2–5} It may be primarily owing to the high rate of false-positive discovery in high-throughput data, in addition to the high degree of genetic variation of individual tumor compared with limited number of samples available for the study.

Received 23 March 2010; revised 10 October 2010; accepted 17 October 2010; published online 21 December 2010

To provide insight into clinically relevant mechanisms for chemotherapy resistance in gastric cancer, we prospectively collected and analyzed 123 endoscopic biopsy samples before cisplatin and fluorouracil (CF) chemotherapy from patients with extended follow-up, using high-throughput transcriptional profiling and comparative genomic hybridization (CGH) analyses. We could identify functional categories enriched in genes correlated with patient outcome, and develop a genomic predictor that was validated in two independent data sets.

Materials and methods

Patients

Sample collection, treatment and follow-up were performed according to a protocol approved by the Institutional Review Board of the National Cancer Center Hospital in Goyang, Korea (NCCNHS01-003). All patients signed an Institutional Review Board-approved informed consent form. Eligibility for enrollment into the study included the following parameters: (1) age ≥ 18 years; (2) histologically confirmed gastric adenocarcinoma; (3) clinically documented distant metastasis; (4) no previous or concomitant malignancies other than the gastric cancer; (5) no previous history of chemotherapy, either adjuvant or palliative; and (6) adequate function of all major organs. Patients who were lost to follow-up before completing six cycles of chemotherapy, except for documented progressive disease, were excluded from this study.

Sample size calculation

Overall survival was the primary clinical end point of this study. As a minimum of 91 events were estimated to be required for the number of training set samples⁶ at $\alpha = 0.001$, $\beta = 0.05$, τ (standard deviation of log intensity) = 0.75 and δ (hazard ratio (HR) associated with one-unit change of log intensity) = 2, we used the 96 samples collected until January 2005 as the training set for development of the predictor.

Ninety-six eligible patients who were treated with CF by one medical oncologist (HK) from August 2001 to January 2005 were used for the expression profiling training set. A second group of 27 eligible patients was used as the array validation cohort. Twenty-two patients in the validation cohort were treated with CF, and five patients were treated with cisplatin plus oral capecitabine (a fluorouracil pro-drug considered equivalent to fluorouracil; CX),⁷ by another group of medical oncologists in the same institution between February 2005 and April 2006. Tissue procurement and processing were the same for the training and validation samples.

Treatment

Patients continued therapy indefinitely until they experienced unacceptable toxicities or progressive disease was documented. CF-treated patients received cisplatin 60 mg m^{-2} intravenously on day 1 and fluorouracil 1000 mg m^{-2} intravenously on days 1–5 of a 3-week

schedule. The treatment schedule for fluorouracil could be shortened at the discretion of the oncologist to 3 instead of 5 days for elderly patients (≥ 70 years) or patients with poor performance status (Eastern Cooperative Oncology Group performance status ≥ 2). Chemotherapy doses were reduced according to toxicities and the patient's performance status. Specific dose modification schemes for the subsequent cycle were left to the discretion of treating oncologist. Five patients (18.5%) in the validation group received oral capecitabine (Xeloda; Roche, Basel, Switzerland; 1250 mg m^{-2} twice a day for 2 weeks) instead of intravenous infusion of fluorouracil. Time to progression was measured from the initiation of chemotherapy to the progressive disease. In patients without any measurable lesions, time to progression was measured to the time when a change in therapy was required because unmeasurable lesions (such as ascites) unequivocally progressed.

Gene expression and CGH microarray analyses

Tissue samples were collected and processed for RNA and DNA extraction as described previously,⁸ only if samples contained at least 50% tumor cells. Affymetrix (Santa Clara, CA, USA) HG-U133A gene expression microarray data were analyzed with survival analysis algorithms of BRB-ArrayTools (version 3.6, National Cancer Institute, <http://linus.nci.nih.gov/BRB-ArrayTools.html>).⁹ The survival risk groups were constructed using a predictive index based on the supervised principal component method of Bair and Tibshirani.¹⁰ A three-gene predictive index percentile was generated based on the weighted average of the log intensities of the three genes (*FGFR2* (211401_s_at), *EGFR* (210984_x_at) and *c-MYC* (202431_s_at)), using a proportional hazards regression on the first two principal components of the log intensities of those three genes, in which a high value of the predictive index corresponds to a high risk of death. If the predictive index of a sample in the validation set corresponded to the median predictive index of the training set, the sample was assigned a 50% predictive index. We specified the number of risk groups as 2 (high and low) and the predictive index percentile for defining the two risk groups as 67%, using a 67.1% rate of clinical benefit (partial response and stable disease) and 32.9% rate of progressive disease in the training set. We also performed Cox regression analyses using this three-gene predictive index percentile as a continuous variable, in which HRs for survival were calculated according to each percentile increase in three-gene predictive index percentile (from 0 to 100%). Array CGH data were generated using Agilent (Santa Clara, CA, USA) $4 \times 44\text{k}$ HD-CGH Microarrays and analyzed using CGH Analytics software (version 3.5.14). Aberrations with average tumor/normal \log_2 ratio > 2.0 were defined as amplifications. Experimental details are provided in Supplementary Materials and Methods.

Analyses of published DNA microarray data

The entire set of published Affymetrix U133 Plus 2.0 DNA microarray data⁴ ($n = 40$) was combined with our training set data ($n = 96$), using common probe set IDs. MAS5 data of

the combined data set were log₂ transformed, normalized using the median over the entire arrays and analyzed for survival risk prediction using BRB-ArrayTools 3.6, as described above.

Publicly accessible microarray data for surgically treated gastric cancer patients generated by the Stanford Functional Genomics Facility were obtained from the NCBI GEO database (GSE4007) and included about 30 300 genes common to these data sets. The microarray data were generated and normalized as described in Leung *et al.*¹¹ Batch effects in gene expression were removed with probe-wise mean centering and missing data were imputed with the nearest-neighbor averaging method.¹² The array cDNA clones were annotated using SOURCE (Stanford Microarray Database) and the Entrez GeneID was used as the mapping identifier for the Affymetrix HG-U133A array. A combined data set of our training set data (*n*=96) and GSE4007 data (*n*=88) was analyzed for survival risk prediction using BRB-ArrayTools 3.6 as described above.

Results

Genes correlated with poor survival after CF therapy

As primary gastric cancer lesions cannot be reliably measured by diagnostic imaging, patient survival, not radiographic response, was used as the primary clinical covariate to which gene expression was correlated to identify a predictor of response to CF therapy. To define a gene expression signature that correlates with overall survival, we used expression array data of 96 pretreatment biopsy samples as the training set to develop a predictor (Supplementary Table 1). Ninety-five out of 96 patients (99%) in the training set cohort died with follow-up for one survivor at 39.4 months. None of the clinicopathological or treatment factors listed in Table 1, including second-line chemotherapy, were significantly correlated with survival time of the patients in the training set.

To identify a transcriptional profile related to clinical benefit from CF therapy, the survival times of patients in the array training set were correlated with the mRNA expression levels measured by microarray. One thousand five hundred and sixty-five genes were significantly correlated with the overall survival of the 96 patients (*P*-value <0.05). Among them, 917 genes had an HR higher than 1 (poor prognosis signature) and 648 genes had an HR lower than 1 (good prognosis signature). We performed gene ontology analyses on this 'poor prognosis signature' using Ingenuity Pathway Analysis (www.ingenuity.com). The role of *BRCA1* in DNA damage response (*BRCA2*, *E2F5*, *FANCE*, *MSH2*, *NBN*, *PLK1*, *RFC*, *SMARCA4*, *SLC19A1*), nucleotide excision repair (*ERCC2*, *POLR2C*, *POLR2J*, *RAD23A*, *RAD23B*) and estrogen receptor signaling were highly represented canonical pathways. Many of these *poor prognosis signature* genes belonging to these three pathways are previously linked to *in vitro* cisplatin resistance.^{13–15} Overexpression of *ERCC2* (*P*=0.007 in our data) is associated with cisplatin resistance in lung cancer cell lines.¹³ Silencing of hHR23A (*P*=0.022 in our

Table 1 Clinicopathological characteristics of patients

	Training set (<i>n</i> =96)	Validation set (<i>n</i> =27)
<i>Baseline clinicopathological characteristic</i>		
Age, no. (%)		
<70 years	90 (93.8%)	25 (92.6%)
≥70 years	6 (6.2%)	2 (7.4%)
Sex, no. (%)		
Male	73 (76.0%)	23 (85.2%)
Female	23 (24.0%)	4 (14.8%)
PS, no. (%)		
ECOG PS 0 or 1	91 (94.8%)	25 (92.6%)
ECOG PS 2 or 3	5 (5.2%)	2 (7.4%)
Histological type, no. (%)		
Lauren's intestinal	40 (41.7%)	9 (33.3%)
Lauren's diffuse	56 (58.3%)	18 (66.6%)
Location of primary lesion, no. (%)		
Upper 1/3	14 (14.6%)	2 (7.4%)
Middle 1/3	28 (29.2%)	10 (37.0%)
Lower 1/3	49 (51.0%)	15 (55.6%)
Entire stomach	5 (5.2%)	0
Distant metastasis, no. (%)	96 (100%)	27 (100%)
Tumor cell percentage in sample (%)		
Median	60	70
Interquartile range	50–70	55–80
<i>Treatment and outcome</i>		
Chemotherapy regimen, no. (%)		
Cisplatin/fluorouracil	96 (100%)	22 (81.5%)
Cisplatin/capecitabine	0 (0%)	5 (18.5%)
Relative dose intensity (%)		
Median	79	81
Interquartile range	73–88	72–87
Number of chemotherapy cycles		
Median	4	7
Interquartile range	3–9	5–13
Response (WHO criteria), no. (%)		
PR	38 (44.7%)	12 (48.0%)
SD	19 (22.4%)	9 (36.0%)
PD	28 (32.9%)	4 (16.0%)
Non-measurable disease	11	2
Second-line chemotherapy, no. (%)	69 (71.9%)	19 (70.4%)
Median follow-up for survivors (months)	39.4	30.4
Overall survival (months)		
Median	8.1	12.6
Interquartile range	5.6–15.9	7.4–30.4
Time to progression (months)		
Median	3.9	6.3
Interquartile range	2.2–8.3	3.9–14.6

Abbreviations: ECOG, Eastern Cooperative Oncology Group; PD, progressive disease; PR, partial response; PS, performance status; SD, stable disease; WHO, World Health Organization.

data) decreases the nuclear DRP1 level and cisplatin resistance in lung adenocarcinoma cells.¹⁴ Disruption of the Fanconi anemia–BRCA pathway is reported in cisplatin-sensitive ovarian tumors.¹⁵ Thus, this gene ontology analysis supports the clinical relevance of these DNA repair

canonical pathways, which were shown to be associated with *in vitro* cisplatin resistance.

Ingenuity Pathway Analysis functional categories enriched in poor prognosis signature were: protein synthesis, DNA replication/recombination/repair and cancer (Supplementary Table 2). The protein synthesis category includes ribosomal subunit mRNAs (*RPL13*, *RPL18*, *RPL24*, *RPL30*, *RPL38*, *RPL5*, *RPL7*, *RPL7A*, *RPL8*, *RPS2*, *RPS5*) and eukaryotic translation initiation factors (*EIF1*, *EIF2B2*, *EIF2B4*, *EIF2S1*, *EIF3B*, *EIF3C*, *EIF3D*, *EIF3E*, *EIF3F*, *EIF3H*, *EIF3I*, *EIF4A1*, *EIF4A3*, *EIF4B*, *EIF4EBP1*, *EIF5*, *EIF5B*). This result suggests that the most prominent feature of poor prognosis signature is increased protein synthesis, presumably resulting from activation of oncogenes, such as *EGFR*, *FGFR2* and *MYC* (Supplementary Table 2). *MYC*-induced transcriptional activation of protein synthesis-related genes is previously shown by a microarray report that the majority of genes responsive to *MYC* overexpression are involved in macromolecular synthesis, protein turnover and metabolism, including 30 ribosomal protein genes.¹⁶

Infinitesimal perturbation analysis canonical pathways enriched in 648 genes in good prognosis signature were antigen presentation pathway, B-cell development and interleukin-15 production. Enriched functional categories were gastrointestinal disease, inflammatory disease and genetic disorder.

Development of the three-gene predictor

Although such a gene ontology analysis of the whole signature provides some insight into clinically relevant mechanisms for chemotherapy resistance, this large number of genes is not readily amenable to clinical application. Therefore, we wished to narrow down 917 genes in the whole poor prognosis signature to the smaller number of genes, which may have driven the expression of majority of genes in the signature. Focusing on such 'driver gene' candidates would also minimize the chance of including false-positive discovery in a genomic predictor. For this purpose, a second tier of genomic analysis was performed to identify genes that could be functionally important in gastric cancer cells.

Genomic DNA from samples available from the training set patients was analyzed by array CGH to identify gene amplifications. Age, sex and overall survival were similar between the 30 patients (31.3%) whose samples were analyzed by array CGH and the other patients in the training set. Using very conservative criteria (average tumor/normal \log_2 ratio >2.0 for ≥ 5 consecutive CGH probes), nine amplicons were identified in 11 patients (Table 2). We identified genes found in both the 1565 gene expression signature whose transcriptional levels correlated with poor survival of 96 training set patients (P -value <0.05) and that are also located within the nine amplicons identified by the array CGH. Three genes—*MYC* (8q24.13–24.21), *EGFR* (7p11.2) and *FGFR2* (10q26)—were identified in the amplicons (Table 2) whose expression array signal values significantly correlated with the survival time of the 96 patients in the training set (Figure 1). Patients with *EGFR*

Table 2 Amplicons identified using array CGH^a

Cytoband	Start	End	Target gene	No. of patients
3q27.1	185 763 900	185 763 959	<i>EPHB3</i>	1
5q33.1	149 481 646	149 514 673	<i>PDGFRB</i>	1
7p11.2	54 746 103	55 363 004	<i>EGFR</i>	1
8q24.13–24.21	126 357 675	128 822 455	<i>MYC</i>	2
9p13.3	33 745 689	33 961 753	<i>PRSS3</i> , <i>UBE2R2</i> , <i>UBAP2</i>	1
10q26	123 264 724	13 123 458 467	<i>FGFR2</i>	2
17q12	35 046 052	35 282 145	<i>ERBB2</i>	2
17q21.2	36 110 139	36 230 022	<i>KRT24</i> , <i>KRT25A</i> , <i>KRT25C</i> , <i>KRT25D</i> , <i>KRT10</i>	2
17q21.2	36 569 493	36 888 515	<i>KRTAP4-4</i> , <i>KRTAP4-10</i> , <i>KRTAP9-9</i> , <i>KRTAP9-4</i> , <i>KRTAP17-1</i> , <i>KRTHA3A</i> , <i>KRTHA3B</i> , <i>KRTHA4</i> , <i>KRTHA1</i> , <i>KRTHA7</i> , <i>KRTHA8</i> , <i>KRTHA2</i> , <i>KRTHA5</i>	1

Abbreviation: CGH, comparative genomic hybridization.

^aDefined by aberrations with average tumor/normal \log_2 ratio >2.0 for ≥ 5 consecutive probes.




Figure 1 Three genes—*EGFR*, *FGFR2* and *MYC*—overlap between genes whose array expression levels correlated with survival times (96 training set patients, $P < 0.05$) and gene copy number changes determined by array comparative genomic hybridization (CGH) (tumor/normal \log_2 ratio >2 for ≥ 5 consecutive probes).

and *FGFR2* amplifications had higher expression levels of each gene (8.4 and 10.2 ± 0.8 (mean \pm s.d.), for *EGFR* and *FGFR2*, respectively) than tested patients without the amplification of these genes (5.9 ± 1.0 and 5.2 ± 1.1 , for *EGFR* and *FGFR2*, respectively). One of the two patients with *MYC* amplification had higher expression than patients without amplification (10.9 vs 9.5 ± 0.9).

The mRNA expression array signal values of these three genes were correlated with the short survival time with P -values of 0.0154, 0.0096 and 0.0057, for *MYC*, *EGFR* and *FGFR2*, respectively. The expression patterns of these three

genes along with the cumulative survival data for all patients are depicted in the heatmap in Figure 2. None of the three genes had significantly different expression levels between those patients who received second-line chemotherapy and those who did not. Quantitative real-time RT-PCR and immunohistochemical staining for the three genes validated the array expression data (Supplementary Figures 1 and 2).

A three-gene predictive index percentile was then calculated for each of the 27 patients in the validation cohort, based on the weighted average of the log intensities of these three genes for each sample (designated as the three-gene

predictor). Patterns of *MYC*, *EGFR* and *FGFR2* expression in these 27 patients, together with the predictive index, are graphically displayed in Figure 2. As a continuous variable, the three-gene predictive index percentile is an independent predictor for poor survival in the validation set by Cox regression analyses, after considering age, performance status, histological type and second-line chemotherapy (adjusted $P=0.017$) (Table 3). Patients predicted to have poor survival after CF using a predictive index percentile $\geq 67\%$ had a significantly shorter median survival than patients with a predictive index percentile $<67\%$ (7.4 months for the high-risk group vs 16.8 months for the




Figure 2 Affymetrix array expression levels of *MYC*, *EGFR* and *FGFR2* in 96 training set samples (left) and 27 validation set samples (right), shown with Kaplan–Meier plots for overall survival. Samples are ordered by the increasing survival period of patient from left to right, for the training and validation sets, respectively. A three-gene predictive index for each patient based on the three-gene predictor is indicated below.

Table 3 Cox regression analyses of the three-gene predictive index percentile, as a continuous variable, for 27 patients in the validation set

	Overall survival		Time to progression	
	P-value	HR (95% CI)	P-value	HR (95% CI)
<i>Univariate</i>				
Three-gene predictive index percentile ^a	0.050	1.015 ^b (1.000–1.030)	0.026	1.017 (1.002–1.031)
<i>Multivariate</i>				
Three-gene predictive index percentile	0.017	1.023 (1.004–1.042)	0.014	1.023 (1.005–1.043)
Age ≥ 70 years ^c	0.027	7.614 (1.257–46.130)	0.144	3.605 (0.646–20.112)
Poor performance status (ECOG PS 2 or 3)	0.346	2.130 (0.442–10.258)	0.074	4.829 (0.861–27.086)
Second-line chemotherapy	0.041	4.231 (1.064–16.831)	0.011	5.992 (1.502–23.902)
Diffuse histological type	0.773	1.164 (0.415–3.263)	0.280	1.774 (0.626–5.025)

Abbreviations: CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio.

^aComputed based on weighted average of log intensities of the three genes (*EGFR*, *FGFR2* and *MYC*) obtained using a proportional hazards regression on the first two principal components of the log signal intensities of those three genes.

^bHR for each percentile increase in three-gene predictive index percentile. For example, a predictive index percentile of 100 (the highest predictive index) is associated with an HR of 4.4 ($= 1.015^{100}$), compared with a predictive index percentile of 0 (the lowest predictive index). The median predictive index (50%) is associated with HRs of 2.1 ($= 1.015^{50}$), compared with the lowest predictive index.

^cFor patients aged ≥ 70 years, the treatment schedule for fluorouracil could be shortened at the discretion of the oncologist to 3 instead of 5 days.

low-risk cohort; $P=0.047$) (Figure 3a). As a class, the high-risk group predicted by the three-gene predictor (patient group with a predictive index percentile $\geq 67\%$) was associated with an adjusted HR of 3.1 (95% CI, 1.2–8.4;




Figure 3 (a) Kaplan–Meier survival curves for the two risk groups of the validation cohort predicted by three-gene predictor. Patients at a high risk (predictive index percentile $\geq 67\%$; $n=10$) had significantly shorter median survival than patients at a low risk ($n=17$) (7.4 vs 16.8 months; log rank $P=0.047$). Green and blue lines represent overall survival curves for the predicted high- and low-risk groups, respectively. (b) Kaplan–Meier survival curves for the two risk groups of the published microarray data set from 40 metastatic gastric cancer patients treated with either fluorouracil-based regimens or cisplatin/irinotecan combination chemotherapy regimen. Patients at a high risk (predictive index percentile $\geq 67\%$; $n=6$) had shorter median survival than patients at a low risk ($n=34$), at a borderline significance (3.1 vs 10.8 months; log rank $P=0.056$). Green and blue lines represent overall survival curves for the predicted high- and low-risk groups, respectively. The color reproduction of the figure is available on the html full text version of the manuscript.

$P=0.022$). In addition, the three-gene predictive index percentile is also an independent predictor for the time to progression, which is a more specific indicator of the clinical responsiveness to systemic therapy than overall survival¹⁷ (adjusted $P=0.014$) (Table 3). We therefore show that, independent of old age (≥ 70 years), poor performance status (Eastern Cooperative Oncology Group performance status ≥ 2) and second-line chemotherapy, the three-gene predictive index is predictive of the benefit from CF to metastatic gastric cancer patients. An adjusted HR for time to progression according to each percentile increase in three-gene predictive index percentile was 1.023 (95% CI, 1.005–1.043) (that is, 100, 75 and 50% predictive indices are associated with an HR of 9.7 ($=1.023^{100}$), 5.5 ($=1.023^{75}$) and 3.1 ($=1.023^{50}$), respectively, compared with a 0% predictive index).

Three-gene predictor predicts survival of patients in the second validation set

To extend these results, we wished to test the predictive power of the three-gene predictor in other independent data sets. After the three-gene predictor was validated in 27 patient samples in our validation set, another microarray study with a comparable study design to our study was published in the literature.⁴ These data were only one published microarray data set that could be used to determine whether the three-gene predictor could predict the outcome of metastatic gastric cancer patients treated with either cisplatin or fluorouracil. This data set contains pretreatment expression array data for 40 patients who subsequently received either fluorouracil-based chemotherapy ($n=24$) or cisplatin/irinotecan combination chemotherapy ($n=16$) and patient survival data. We applied the same three-gene predictor to this published microarray data set, just as we did to our 27 patient data in the first validation set. The three-gene predictive index percentile, as a continuous variable, was found to be significantly associated with poor survival of these 40 patients ($P=0.047$; HR according to each percentile increase in three-gene predictive index percentile = 1.014 (95% confidence interval, 1.000–1.027)). Cox multivariate analysis showed that the three-gene predictive index percentile is an independent predictor for poor survival, after considering performance status, age, sex and the chemotherapy regimen (adjusted $P=0.026$; adjusted HR = 1.017 (1.002–1.032)) (Table 4, Figure 3b). Thus, the predictive power of the three-gene predictor is consistent across two validation sets, that is, one from our study patients and the other from published data.

Interestingly, the three-gene predictor was found to be an independent predictor for poor survival, when the same Cox regression analysis was performed only on a subset of these patients ($n=16$) treated with cisplatin in combination with irinotecan, a topoisomerase I inhibitor (adjusted $P=0.011$; adjusted HR = 1.038 (1.008–1.068)). Patients treated with irinotecan were not included in the original training set patients. Hence, the predictive power of three-gene predictor may not be specifically associated with only CF therapy, although further large-scale studies need to be

performed to address the predictive value of the three-gene predictor for other therapeutic regimens.

Three-gene predictive index and radiographic response

Although the radiographic tumor response was not the main end point of this study, we also evaluated the association between the three-gene predictive index and radiographic response of patients with measurable disease. When published data⁴ were also included, 104 patients had either

partial response or stable disease (clinical benefit) as the best response, whereas 46 patients had progressive disease. The three-gene predictive index was significantly associated with radiographic response at a univariate *P*-value of 0.039, which is higher than the Cox regression *P*-value for the overall survival of all study patients (Table 5). This statistical association was at borderline significance in a multivariate regression analysis.

Three-gene predictor is not prognostic but predictive

Although we showed that the three-gene predictor predicted time to progression and overall survival for CF-treated patients, we wished to further address whether it represents a prognostic signature, using the published data set from 88 gastric cancer patients who were treated by surgery alone and not with chemotherapy.¹¹ The three-gene predictive index percentile was not a prognostic factor in this data set as a continuous variable (*P* = 0.506). There was no difference in survival in the surgically treated patients between the high- and low-risk groups predicted by the three-gene predictor (*P* = 0.972). These results strongly suggest that the three-gene predictor is not a predictor of prognosis for gastric cancer patients, but is predictive of the patient response to chemotherapy.

Discussion

Cytotoxic chemotherapy prolongs the median survival of metastatic gastric cancer patients from 3–5 to 9–11 months compared with best supportive care, with a response rate of 40–50%.^{18–21} Combination CF constitutes the backbone for chemotherapy regimens commonly used for gastric cancers.^{19,22} We also reported that CF in combination with low-dose docetaxel is active for metastatic gastric cancer with tolerable toxicity profile.¹⁸ The ability to predict the primary resistance of common solid tumors to cytotoxic

Table 4 Cox regression analyses of the three-gene predictive index percentile, as a continuous variable, for published DNA microarray data from 40 metastatic gastric cancer patients treated with either FU-based chemotherapy or cisplatin/irinotecan combination chemotherapy

	Overall survival	
	<i>P</i> -value	HR (95% CI)
<i>Univariate</i>		
Three-gene predictive index percentile	0.047	1.014 (1.000–1.027)
<i>Multivariate</i>		
Three-gene predictive index percentile	0.026	1.017 ^a (1.002–1.032)
Performance status ≥ 1	0.028	3.008 (1.129–8.016)
Age ^b	0.766	0.995 (0.961–1.030)
Male	0.538	1.359 (0.512–3.605)
FU-based chemotherapy regimen ^c	0.744	0.854 (0.332–2.199)

Abbreviations: CI, confidence interval; FU, fluorouracil; HR, hazard ratio.

^aAdjusted HR for each percentile increase in three-gene predictive index percentile. For example, a predictive index percentile of 100 (the highest predictive index) is associated with an HR of 5.4 (= 1.017¹⁰⁰), compared with a predictive index percentile of 0 (the lowest predictive index).

^bAs a continuous variable.

^cAs compared with the irinotecan/cisplatin combination chemotherapy regimen.

Table 5 Logistic regression analysis on the three-gene predictive index for radiographic response of 150 patients with measurable disease, including patients represented by the published data set

	Radiographic response ^a		Time to progression		Overall survival	
	<i>P</i> -value	OR (95% CI)	<i>P</i> -value ^b	HR (95% CI)	<i>P</i> -value ^c	HR (95% CI)
<i>Univariate</i>						
Three-gene predictive index ^d	0.039	2.001 (1.036–3.864)	0.020	1.304 (1.042–1.631)	0.030	1.288 (1.026–1.618)
<i>Multivariate</i>						
Three-gene predictive index	0.059	1.902 (0.976–3.704)	0.019	1.309 (1.045–1.641)	0.018	1.316 (1.048–1.654)
Age ≥ 70 years	0.914	1.069 (0.318–3.598)	0.791	1.119 (0.486–2.577)	0.113	1.600 (0.895–2.862)
Poor performance status (ECOG PS 2 or 3)	0.336	0.513 (0.132–1.999)	0.026	2.192 (1.097–4.381)	0.048	1.921 (1.004–3.677)

Abbreviations: CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; OR, odds ratio; WHO, World Health Organization

^aNo clinical benefit (progressive disease according to the WHO criteria; *n* = 46) vs clinical benefit (partial response and stable disease; *n* = 104).

^bResult of Cox regression analysis on the three-gene predictive index for the time to progression of 123 patients in the training and the first validation sets.

^cResult of Cox regression analysis on the three-gene predictive index for the overall survival of all of 163 study patients including published data set.

^dComputed based on weighted average of log intensities of the three genes (*EGFR*, *FGFR2* and *MYC*) obtained using a proportional hazards survival regression on the first two principal components of the log signal intensities of those three genes.

chemotherapy is currently lacking, but would significantly improve patient care by identifying those who would best be treated by alternative strategies. This study has identified a three-gene predictor that distinguishes gastric cancer patients likely to receive a therapeutic benefit from CF from those who will not.

Most previous studies attempting to identify predictors of chemoresistance in gastric cancer have examined only individual genes such as *TS* or *ERCC1*.^{23,24} High-throughput DNA microarray analyses to identify gene expression signatures predictive of chemotherapy or chemoradiotherapy resistance in gastrointestinal cancer patients have been limited by the small number of samples,^{2,3} heterogeneous treatment⁴ or were not prospectively designed.⁵ In contrast to these previous studies, our study uses high-throughput genomic approaches, is prospective with a large, pre-defined number of training set patients, separate validation cohorts and survival data during an extended follow-up period. Although previously reported *TS* and *ERCC1* tend to be associated with poor prognosis of our patients, the association was not significant enough for them to be considered for our predictive model ($P=0.073$ and 0.076 , for *TS* and *ERCC1*, respectively). Notably, the outcome discrimination predicted by the classifier was statistically significant on two validation groups, including the only available published microarray data set from chemotherapy-treated gastric cancer patients.⁴ Although the sample size of our validation set is relatively small, it is nonetheless large enough to show that our three-gene predictor provides a statistically significant discrimination of patient outcome in multivariate survival analyses. The study design we employed is consistent with an allocation of two-thirds to one-third training-to-test set sample allocation as recommended by statisticians.²⁵

We combined analyses of gene expression changes identified by expression profiling with the identification of DNA copy number changes using array CGH to develop a predictor composed of a much smaller number of critical genes that potentially could be of clinical utility. We identified *MYC*, *EGFR* and *FGFR2* in regions of amplification, as well as in the gene expression signature related to clinical outcome after CF therapy, suggesting that these genes might be functionally involved in determining resistance. Amplification of *MYC*, *EGFR* and *FGFR2* have previously been observed in gastric cancer at frequencies 4.8–15.5%,²⁶ 2.3–13.3%²⁷ and 3–10%,^{26,28} respectively, suggesting that, in some cases, tumors amplify these regions for selective advantage. Combined expression of these three genes could predict overall survival and time to progression of CF-treated gastric cancer patients. Thus, combining array CGH analysis with relevant transcriptional changes is a feasible approach for building a predictive model using functionally important genes and reducing the likelihood of false biomarker discovery. Transcriptional levels of genes other than *MYC*, *EGFR* and *FGFR2* identified in the amplified genomic loci were not associated with the survival of the 96 training set patients (for example, $P=0.313$ for *ERBB2*).

Primary gastric tumors are not easily measurable by current radiographic techniques, and often there are no metastatic lesions that are readily quantifiable in metastatic gastric cancer patients. To develop a predictor from the general population of gastric cancer patients in an unbiased way, this study was designed to correlate gene expression profiling of the tumors with overall survival and time to progression, not radiographic response. Overall survival is the ultimate measure of the treatment benefit afforded to a patient and is a particularly appropriate gauge for patients with metastatic gastric cancer, as radiographic assessment is problematic in such patients. The fact that both the time to progression as well as overall survival are predicted by our three-gene predictor in CF-treated patients, but not surgically treated patients, suggests that the three-gene predictor is a predictive indicator for the clinical benefit from CF.

Although *EGFR* and *FGFR2* expression have been reported to have prognostic value for gastric cancer patients treated surgically,^{29,30} we did not find the three-gene predictive index to be prognostic for surgically treated patients with gastric cancer. Our findings are consistent with previously reported experimental data on chemoresistance. Inhibitors of *EGFR* act synergistically with cisplatin³¹ and fluorouracil,³² whereas an *FGFR2* inhibitor is synergistic with fluorouracil.³³ *MYC* has been linked to cisplatin resistance in several *in vitro* models.^{34–37}

Taken together, combined expression of *MYC*, *EGFR* and *FGFR2* is predictive of poor survival in CF-treated metastatic gastric cancer patients. More focused prospective trials that are designed to test the clinical utility of this three-gene predictor are warranted.

Conflict of interest

The authors declare no conflict of interest.

Acknowledgments

The work was supported in part by National Institute of Health Intramural Program, Center for Cancer Research, National Cancer Institute, Korean National Cancer Center Grant 0910570 and Converging Research Center Program through the Ministry of Education, Science and Technology of Korea (2010K001121). We thank Dr Richard Simon for valuable discussions and critical reading of the manuscript, Dr Lyuba Varticovski for critical review of the manuscript and Dr Chang-Hee Kim, Ms Susie Korolevich, Ms Eunbyul Lee, Ms Eugene Kim and Ms Ilji Jeon for technical help.

Transcript Profiling

All expression microarray data is available at Gene Expression Omnibus (accession number GSE14210; <http://www.ncbi.nlm.nih.gov/geo>).

References

- 1 Uchida K, Danenberg PV, Danenberg KD, Grem JL. Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastro-

- intestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine. *BMC Cancer* 2008; **8**: 386.
- 2 Ghadimi BM, Grade M, Difilippantonio MJ, Varma S, Simon R, Montagna C *et al*. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. *J Clin Oncol* 2005; **23**: 1826–1838.
 - 3 Rimkus C, Friederichs J, Boulesteix AL, Theisen J, Mages J, Becker K *et al*. Microarray-based prediction of tumor response to neoadjuvant radiochemotherapy of patients with locally advanced rectal cancer. *Clin Gastroenterol Hepatol* 2008; **6**: 53–61.
 - 4 Yamada Y, Arai T, Gotoda T, Taniguchi H, Oda I, Shirao K *et al*. Identification of prognostic biomarkers in gastric cancer using endoscopic biopsy samples. *Cancer Sci* 2008; **99**: 2193–2199.
 - 5 Allen WL, Coyle VM, Jithesh PV, Proutski I, Stevenson L, Fenning C *et al*. Clinical determinants of response to irinotecan-based therapy derived from cell line models. *Clin Cancer Res* 2008; **14**: 6647–6655.
 - 6 Simon R, Radmacher MD, Dobbin K. Design of studies using DNA microarrays. *Genet Epidemiol* 2002; **23**: 21–36.
 - 7 Kang Y, Kang WK, Shin DB, Chen J, Xiong J, Wang J *et al*. Randomized phase III trial of capecitabine/cisplatin vs continuous infusion of 5-FU/cisplatin as first-line therapy in patients with advanced gastric cancer: efficacy and safety results. *J Clin Oncol* 2006; **24** (Suppl): 18s (abstract 4018).
 - 8 Kim HK, Choi JJ, Kim HS, Kim JH, Kim E, Park IS *et al*. DNA microarray analysis of the correlation between gene expression patterns and acquired resistance to 5-FU/cisplatin in gastric cancer. *Biochem Biophys Res Commun* 2004; **316**: 781–789.
 - 9 Simon R, Lam A, Li MC, Ngan M, Menenzes S, Zhao Y. Analysis of gene expression data using BRB-Array Tools. *Cancer Informatics* 2007; **2**: 11–17.
 - 10 Bair E, Tibshirani R. Semi-supervised methods to predict patient survival from gene expression data. *PLoS Biol* 2004; **2**: E108.
 - 11 Leung SY, Chen X, Chu KM, Yuen ST, Mathy J, Ji J *et al*. Phospholipase A2 group IIA expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastasis. *Proc Natl Acad Sci USA* 2002; **99**: 16203–16208.
 - 12 Troyanskaya O, Cantor M, Sherlock G, Brown P, Hastie T, Tibshirani R *et al*. Missing value estimation methods for DNA microarrays. *Bioinformatics* 2001; **17**: 520–525.
 - 13 Weaver DA, Crawford EL, Warner KA, Elkhairi F, Khuder SA, Willey JC. ABCG5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. *Mol Cancer* 2005; **4**: 18–25.
 - 14 Chiang YY, Chen SL, Hsiao YT, Huang CH, Lin TY, Chiang IP *et al*. Nuclear expression of dynamin-related protein 1 in lung adenocarcinomas. *Mod Pathol* 2009; **22**: 1139–1150.
 - 15 Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H *et al*. Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors. *Nat Med* 2003; **9**: 568–574.
 - 16 Guo QM, Malek RL, Kim S, Chiao C, He M, Ruffly M *et al*. Identification of c-myc responsive genes using rat cDNA microarray. *Cancer Res* 2000; **60**: 5922–5928.
 - 17 Balko JM, Black EP. A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer. *BMC Cancer* 2009; **9**: 145–154.
 - 18 Park SR, Chun JH, Yu MS, Lee JH, Ryu KW, Choi JJ *et al*. Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma. *Br J Cancer* 2006; **94**: 1402–1406.
 - 19 Park SR, Chun JH, Yu MS, Lee JH, Ryu KW, Choi JJ *et al*. Phase II study of low-dose docetaxel/fluorouracil/cisplatin in metastatic gastric carcinoma. *Am J Clin Oncol* 2005; **28**: 433–438.
 - 20 Cunningham D, Rao S, Starling N, Iveson T, Nicolson M, Coxon F *et al*. Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL 2 trial. *J Clin Oncol* 2006; **24**: 18s (abstr. 4017).
 - 21 Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. *Br J Cancer* 1995; **71**: 587–591.
 - 22 Tetzlaff ED, Cen P, Ajani JA. Emerging drugs in the treatment of advanced gastric cancer. *Expert Opin Emerg Drugs* 2008; **13**: 135–144.
 - 23 Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Groshen S, Cohen H *et al*. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. *J Clin Oncol* 1996; **14**: 176–182.
 - 24 Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K *et al*. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. *J Clin Oncol* 1998; **16**: 309–316.
 - 25 Dobbin KK, Simon RM. Optimally splitting cases for training and testing high dimensional classifiers (submitted for publication) <http://linus.nci.nih.gov/~brb/reprints.htm>.
 - 26 Hara T, Ooi A, Kobayashi M, Mai M, Yanagihara K, Nakanishi I. Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence *in situ* hybridization. *Lab Invest* 1998; **78**: 1143–1153.
 - 27 Moutinho C, Mateus AR, Milanezi F, Carneiro F, Seruca R, Suriano G. Epidermal growth factor receptor structural alterations in gastric cancer. *BMC Cancer* 2008; **8**: 10–15.
 - 28 Yoshida T, Sakamoto H, Terada M. Amplified genes in cancer in upper digestive tract. *Semin Cancer Biol* 1993; **4**: 33–40.
 - 29 Lieto E, Ferraraccio F, Orditura M, Castellano P, Mura AL, Pinto M *et al*. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. *Ann Surg Oncol* 2008; **15**: 69–79.
 - 30 Yasui W, Oue N, Aung PP, Matsumura S, Shutoh M, Nakayama H. Molecular–pathological prognostic factors of gastric cancer: a review. *Gastric Cancer* 2005; **8**: 86–94.
 - 31 Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus *cis*-diamminedichloroplatinum on well established A431 cell xenografts. *Cancer Res* 1993; **53**: 4637–4642.
 - 32 Hiraishi Y, Wada T, Nakatani K, Uchida J, Iwasa T, Yoshida T *et al*. Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase. *Mol Cancer Ther* 2008; **7**: 599–606.
 - 33 Yashiro M, Shinto O, Nakamura K, Tendo M, Matsuoka T, Matsuzaki T *et al*. Synergistic anti-tumor effects of FGFR2 inhibitor with 5-fluorouracil on scirrhous gastric carcinoma. *Int J Cancer* 2010; **126**: 1004–1016.
 - 34 Leonetti C, Biroccio A, Candiloro A, Citro G, Fornari C, Mottolese M *et al*. Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin. *Clin Cancer Res* 1999; **5**: 2588–2595.
 - 35 Xie XK, Yang DS, Ye ZM, Tao HM. Recombinant antisense C-myc adenovirus increase *in vitro* sensitivity of osteosarcoma MG-63 cells to cisplatin. *Cancer Invest* 2006; **24**: 1–8.
 - 36 Knapp DC, Mata JE, Reddy MT, Devi GR, Iversen PL. Resistance to chemotherapeutic drugs overcome by c-Myc inhibition in a Lewis lung carcinoma murine model. *Anticancer Drugs* 2003; **14**: 39–47.
 - 37 Biroccio A, Benassi B, Fiorentino F, Zupi G. Glutathione depletion induced by c-Myc downregulation triggers apoptosis on treatment with alkylating agents. *Neoplasia* 2004; **6**: 195–206.



This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/3.0/>

Supplementary Information accompanies the paper on the The Pharmacogenomics Journal website (<http://www.nature.com/tpj>)

FGFR2 gene amplification and clinicopathological features in gastric cancer

K Matsumoto¹, T Arai¹, T Hamaguchi², Y Shimada², K Kato², I Oda³, H Taniguchi⁴, F Koizumi⁵, K Yanagihara⁶, H Sasaki⁷, K Nishio^{3,1} and Y Yamada²

¹Department of Genome Biology, Kinki University Faculty of Medicine, Osaka 589-8511, Japan; ²Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan; ³Endoscopic Division, National Cancer Center Hospital, Tokyo 104-0045, Japan; ⁴Pathology Division, National Cancer Center Hospital, Tokyo 104-0045, Japan; ⁵Shien Lab, National Cancer Center Hospital, Tokyo 104-0045, Japan; ⁶Department of Life Sciences, Yasuda Women's University Faculty of Pharmacy, 6-1-3-1, Ando, Asaminami, Hiroshima 731-0153, Japan; ⁷Division of Genetics, National Cancer Center Research Institute, Tokyo 104-0045, Japan

BACKGROUND: Frequency of *FGFR2* amplification, its clinicopathological features, and the results of high-throughput screening assays in a large cohort of gastric clinical samples remain largely unclear.

METHODS: Drug sensitivity to a fibroblast growth factor receptor (FGFR) inhibitor was evaluated *in vitro*. The gene amplification of the *FGFRs* in formalin-fixed, paraffin-embedded (FFPE) gastric cancer tissues was determined by a real-time PCR-based copy number assay and fluorescence *in situ* hybridisation (FISH).

RESULTS: *FGFR2* amplification confers hypersensitivity to FGFR inhibitor in gastric cancer cell lines. The copy number assay revealed that 4.1% (11 out of 267) of the gastric cancers harboured *FGFR2* amplification. No amplification of the three other family members (*FGFR1*, 3 and 4) was detected. A FISH analysis was performed on 7 cases among 11 *FGFR2*-amplified cases and showed that 6 of these 7 cases were highly amplified, while the remaining 1 had a relatively low grade of amplification. Although the difference was not significant, patients with *FGFR2* amplification tended to exhibit a shorter overall survival period.

CONCLUSION: *FGFR2* amplification was observed in 4.1% of gastric cancers and our established PCR-based copy number assay could be a powerful tool for detecting *FGFR2* amplification using FFPE samples. Our results strongly encourage the development of FGFR-targeted therapy for gastric cancers with *FGFR2* amplification.

British Journal of Cancer (2012) **106**, 727–732. doi:10.1038/bjc.2011.603 www.bjancer.com

Published online 12 January 2012

© 2012 Cancer Research UK

Keywords: *FGFR2*; gastric cancer; gene amplification

Intensive investigations of anticancer treatments for gastric cancer have been done over the past three decades; however, the prognosis for patients with unresectable advanced or recurrent gastric cancer remains poor (Bittoni *et al*, 2010; Fujii *et al*, 2010), and new therapeutic modalities are needed.

Fibroblast growth factors (FGFs) and their receptors are considered to be associated with multiple biological activities, including fundamental developmental pathways, cellular proliferation, differentiation, motility and transforming activities (Itoh *et al*, 1994; Moffa *et al*, 2004; Grose and Dickson, 2005). Fibroblast growth factor signalling is also involved in many physiological roles in the adult organism, such as the regulation of angiogenesis and wound repair, and FGF receptors (FGFRs) are expressed on many different cell types and regulate key cell behaviours of cancer cells (Turner and Grose, 2010). Emerging evidence has demonstrated that the deregulation of FGF signalling is frequently observed in various solid cancers and haematological malignancies (Beenken and Mohammadi, 2009). The most well-known associa-

tion with *FGFR* mutations is the *FGFR3* mutation observed in bladder cancer, in which somatic mutations in coding regions are observed in about 50% of all specimens (Cappellen *et al*, 1999; Turner and Grose, 2010). Other genetic alterations in *FGFR3* include gene amplification in bladder cancer and translocation in myeloma (Turner and Grose, 2010). Similarly, the deregulation of FGF signalling has been reported in various malignancies. Glioblastoma exhibits *FGFR1* kinase domain gain-of-function mutations, and *FGFR1* is abnormally activated in malignant prostate cells. In 8p11 myeloproliferative syndrome, translocations fuse different proteins in frame with the *FGFR1* kinase domain, causing the constitutive dimerisation of the kinase (Giri *et al*, 1999; Rand *et al*, 2005; Beenken and Mohammadi, 2009). The *FGFR1* amplification has been reported in approximately 10% of breast cancers (Courjal *et al*, 1997) and oral squamous carcinomas, and has been also found at a low incidence in ovarian cancer, bladder cancer and rhabdomyosarcoma (Turner and Grose, 2010). *FGFR2* mutations are observed in 12% of endometrial cancers but are reportedly rare in gastric cancers (Jang *et al*, 2001; Dutt *et al*, 2008). The *K-sam* gene was first identified and characterised as an amplified gene in the human gastric cancer cell line KATO-III (Hattori *et al*, 1990; Ueda *et al*, 1999), and its product was later found to be identical to the bacteria-expressed kinase, or

*Correspondence: Dr K Nishio; E-mail: knishio@med.kindai.ac.jp
Received 14 October 2011; revised 16 December 2011; accepted 19 December 2011; published online 12 January 2012

keratinocyte growth factor receptor, and FGF receptor 2 (FGFR2). *FGFR2* amplification has been found in diffuse-type gastric cancer-derived cell lines and the amplification was preferentially detected in diffuse-type gastric cancer. *FGFR2* protein overexpression was detected using immunohistochemical staining in 20 of 38 advanced cases of diffuse-type gastric cancer (Hattori *et al*, 1996). *FGFR2* protein expression was observed in 31% of the gastric carcinomas and was positively correlated with scirrhous cancer, a diffuse type, the invasion depth, the infiltration type and a poor prognosis (Toyokawa *et al*, 2009).

On the other hand, along with another group, we previously reported that *FGFR2* amplification confers hypersensitivity to FGFR inhibitor in gastric cancer cell lines both *in vitro* and *in vivo* (Nakamura *et al*, 2006; Takeda *et al*, 2007), strongly suggesting that *FGFR2* amplification may be a promising molecular target for the treatment of *FGFR2*-amplified gastric cancer. However, very limited information on *FGFR2* amplification is available regarding the frequency, the degree of the increase in the copy number, the histology and a high-throughput screening method in gastric cancer. In this report, we retrospectively studied these issues using formalin-fixed, paraffin-embedded (FFPE) samples in patients with gastric cancer who underwent surgery in an attempt to advance *FGFR2*-targeted therapy for gastric cancer.

MATERIALS AND METHODS

Cell culture

All of the gastric cancer cell lines used in this study were maintained in RPMI-1640 medium (Sigma, St Louis, MO, USA), except for IM95 (DMEM; Nissui Pharmaceutical, Tokyo, Japan), supplemented with 10% heat-inactivated fetal bovine serum (Gibco BRL, Grand Island, NY, USA), penicillin and streptomycin in a humidified atmosphere of 5% CO₂ at 37 °C. IM95 and OCUM1 were obtained from the Japanese Collection of Research Bioresources (Osaka, Japan) and the others were provided from National Cancer Center Research Institute (Tokyo, Japan).

Patients

A total of 267 patients with histologically confirmed gastric cancer who had undergone surgery at the National Cancer Center Hospital between 1996 and 2006 were included in this study. All the patients in this series had an Eastern Cooperative Oncology Group performance status of 0 to 2 and had undergone surgery. Of these patients, one subject was excluded because an insufficient quantity of DNA was extracted from the patient's specimen. Thus, samples from the remaining 267 patients were analysed. This study was approved by the institutional review board of the National Cancer Center Hospital.

Isolation of genomic DNA

Genomic DNA samples were extracted from surgical specimens preserved as FFPE tissue using a QIAamp DNA Micro kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Macro-dissection of the FFPE samples was performed to select a cancer region, which was marked by a pathologist after deparaffinisation. The DNA concentration was determined using the NanoDrop2000 (Thermo Scientific, Waltham, MA, USA).

Real-time reverse-transcription PCR (RT-PCR)

cDNA was prepared from the total RNA of each cultured cell line using a GeneAmp RNA-PCR kit (Applied Biosystems, Foster City, CA, USA). Real-time RT-PCR amplification was carried out using a Thermal Cycler Dice (Takara, Otsu, Japan) in accordance with the manufacturer's instructions under the following conditions:

95 °C for 5 min, and 50 cycles of 95 °C for 10 s and 60 °C for 30 s. The primers used for the real-time RT-PCR were as follows: *FGFR2*, forward 5'-GATAAATACTTCCAATGCAGAAGTGCT-3' and reverse 5'-TGCCCTATATAATTGGAGACCTTACA-3'; *GAPDH*, forward 5'-GCACCGTCAAGGCTGAGAAC-3' and reverse 5'-ATGGTGGTGAAGACGCCAGT-3'. *GAPDH* was used to normalise the expression levels in the subsequent quantitative analyses.

Immunoblotting

A western blot analysis was performed as described previously (Matsumoto *et al*, 2009). The following antibodies were used: monoclonal *FGFR2* antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), β -actin antibody and HRP-conjugated secondary antibody (Cell Signaling Technology, Beverly, MA, USA).

Cell growth inhibitory assay

To evaluate growth inhibition in the presence of various concentrations of PD173074 (Sigma), we used an MTT assay and a previously described method (Kaneda *et al*, 2010). Briefly, the cells were seeded at a density of 2×10^3 cells per well in 96-well plates. After 24 h, PD173074 was added and the incubation was further continued for 72 h at 37 °C. The assay was conducted in triplicate.

Copy number assay for four FGFR family genes

The copy numbers for *FGFR 1-4* were determined using commercially available and pre-designed TaqMan Copy Number Assays according to the manufacturer's instructions (Applied Biosystems). The primer IDs used for *FGFRs* were as follows: *FGFR1*, Hs02862256_cn; *FGFR2*, HS05182482_cn (intron 14) and Hs05114211_cn (intron 12); *FGFR3*, Hs03518314_cn; and *FGFR4*, Hs01949336_cn. The *TERT* locus was used for the internal reference copy number. Human Genomic DNA (Takara) was used as a normal control. Real-time genomic PCR was performed in a total volume of 20 μ l in each well, containing 10 μ l of TaqMan genotyping master mix, 20 ng of genomic DNA and each primer. The PCR conditions were 95 °C for 10 min and 40 cycles of 95 °C for 15 s and 60 °C for 1 min; the resulting products were detected using the ABI PRISM 7900HT Sequence Detection System (Applied Biosystems). Data were analysed using SDS 2.2 software and CopyCaller software (Applied Biosystems).

Fluorescence *in situ* hybridisation analysis

The fluorescence *in situ* hybridisation (FISH) method was previously described (Motoi *et al*, 2010). Probes designed to detect the *FGFR2* gene and the *CEN10p* on chromosome 10 were labelled with fluorescein isothiocyanate or Texas red and were designed to hybridise to the adjacent genomic sequence spanning approximately 0.33 and 0.64 Mb, respectively. The probes were generated from appropriate clones from a library of human genomic clones (GSP Laboratory, Kawasaki, Japan). Deparaffinised tissue sections were air dried and pre-treated with the GSP paraffin pre-treatment kit (GSP Laboratory). In all, 10 μ l of fluorescent FISH probe was heated for 5 min at 73–75 °C in a waterbath for denaturation. The tissue sections were then placed in a denaturant solution (70% formamide/2 \times saline sodium citrate (SSC) pH 7-8) in a 73–75 °C waterbath, denatured for 5 min, dehydrated in 70 and 100% ethanol for 1 min each at room temperature, and air-dried. Denatured probes were applied, and the specimens were covered with a coverglass and placed on a heated block at 45–50 °C. Then, the slides were sealed with rubber cement and placed in a pre-warmed humidified box overnight at 37 °C. Stringent washing was performed using 2 \times SSC/0.3% NP-40 at room temperature and at 72 °C for 5 min and then with 2 \times SSC at room temperature. The signals were observed using fluorescence microscopy, and the

FISH signals were evaluated by independent observers (TM and AK). After screening all the complete sections, images of the tumour cells were captured and recorded and the signals for 20 random nuclei were counted for an area where individual cells were recognised on at least 10 representative images. The positive result of copy number gain is determined as follows ($FGFR2/CEN10p \geq 2.0$).

Statistical analysis

The statistical analyses of the clinicopathological features were performed using the Student *t*-test and the χ^2 test using PAWS Statistics 18 (SPSS Japan Inc., Tokyo, Japan). The overall survival (OS) curves were estimated using the Kaplan–Meier method.

RESULTS

FGFR2 amplification confers hypersensitivity to FGFR inhibitor in gastric cancer cell lines

We examined the growth inhibitory effect of PD173074 (0.004–80 μM) on four *FGFR2*-amplified (HSC-43, TU-KATOIII, SNU-16 and HSC-39) and four non-amplified (44As3, 58As1, IM95 and OCUM1) gastric cancer cell lines. The *FGFR2* amplification status of each cell line had already been examined using a CGH analysis (unpublished data). The mRNA and protein expressions of *FGFR2*

were overexpressed in the *FGFR2*-amplified cell lines (Figures 1A and B). A growth inhibitory assay showed that the IC_{50} values of the *FGFR* inhibitor PD173074 in *FGFR2*-amplified cells were 0.01–0.07 μM , whereas those in non-amplified cells were 2.6–13.2 μM , indicating that *FGFR2* amplification conferred an approximately 100-fold hypersensitivity to *FGFR* inhibitor in gastric cancer cell lines (Figure 1C).

FGFR2 amplification in clinical gastric cancer cell lines and surgical specimens

To develop a high-throughput method for detecting *FGFR2* gene amplification in a clinical setting, we verified a real-time PCR-based detection method, the TaqMan Copy Number Assay. The *FGFR2* copy number was 1.4–2.7 copies in the four non-amplified cell lines; however, the numbers in the four *FGFR2*-amplified cell lines were 28.2, 231.7, 88.2 and 36.3 copies, respectively (Figure 1D). In addition, another primer in intron 12 of *FGFR2* produced a very similar result ($R=0.99$, Figure 1D). Collectively, these results suggested that a DNA copy number assay for *FGFR2* was a sensitive and reproducible method. We also examined the copy numbers of *FGFR1*, *FGFR3* and *FGFR4*, but no obvious gene amplification was observed in all of the eight cell lines (Figure 1D). Next, *FGFR2* amplification was evaluated using the copy number assay in 267 FFPE samples of primary gastric cancer specimens. *FGFR2* amplification of more than 5 copies was observed in 11




Figure 1 *FGFR2* amplification in gastric cancer cell lines. (A) The mRNA expression levels of *FGFR2* were determined using real-time RT–PCR for eight gastric cancer cell lines. *FGFR2* mRNA: normalised mRNA expression levels ($FGFR2/GAPDH \times 10^3$). (B) Western blot analysis for *FGFR2* expression. β -Actin was used as an internal control. Marker, molecular marker. (C) Growth inhibition assay for the *FGFR* inhibitor PD173074, evaluated at the indicated concentrations using an MTT assay. (D) Evaluation of DNA copy number assay using gastric cancer cell lines. A TaqMan copy number assay was performed to determine the copy number using specific primers for the genomic loci of the *FGFR1–4* genes against DNA samples. Amp, gene amplification. *FGFR2*-int-14 and *FGFR2*-int-12, different primers for intron 14 or intron 12 of *FGFR2*.

cases (92.0, 63.0, 41.4, 19.9, 18.4, 13.7, 8.3, 6.2, 6.2, 5.7 and 5.6 copies), with a frequency of 4.1% (Figure 2A). The mean copy number in the non-amplified cases was 2.4 ± 0.6 copies. Meanwhile, no obvious gene amplification of *FGFR1*, *FGFR3* or *FGFR4* was observed (data not shown).

FISH analysis for *FGFR2* amplification

We used a FISH analysis to examine *FGFR2* amplification in the same samples to verify the results of the above PCR-based DNA copy number assay. Highly amplified TU-KATOIII cells showed numerous and large clustered signals, whereas non-amplified OCUM1 cells contained two normally paired signals (Figure 2B). A FISH analysis was performed on seven cases among 11 *FGFR2*-amplified cases and two non-amplified cases. The FISH analysis revealed that *FGFR2* was highly amplified in six of the seven *FGFR2*-amplified clinical samples (four showed multiple scattered signals and two showed large clustered signals), while the remaining sample exhibited a relatively low grade of amplification (*FGFR2*/CEN10p = 2.2, Figure 2B). The *FGFR2* signals in the G3 and G10 samples, which were determined not to be amplified based on the results of the DNA copy number assay, were not increased. These results clearly demonstrated the presence of *FGFR2*-amplified gastric cancers among clinical samples.

Clinicopathological features of *FGFR2*-amplified gastric cancer

We evaluated the clinicopathological features including age, sex, histology and pathological stage according to the *FGFR2* amplification status. Patients age with *FGFR2* amplification were significantly higher than the others, but sex and pathological stage were not associated with *FGFR2* amplification in this study (Table 1). Among the patients with *FGFR2* amplification, the

Table 1 Frequency of *FGFR2* amplification in gastric cancers and its association with clinical and pathologic factors

	FGFR2 (+)		FGFR2 (-)		P-value
	n = 11	%	n = 256	%	
Age					
Range	55-91		31-88		0.047
Median	67		63		
Gender					
Male	11	100	173	68	0.052
Female	0	0	83	32	
pStage					
I	0	0	25	10	0.16 ^a
II	0	0	32	13	
III	3	27	73	29	
IV	8	73	125	49	
Unknown	0	0	1	0	
Histology					
Tub1	0	0	41	16	0.55 ^b
Tub2	2	18	51	20	
Pap	1	9	5	2	
Muc	2	18	8	3	
Sig	1	9	15	6	
Por1	0	0	28	11	
Por2	5	45	108	42	

Abbreviations: Amp = gene amplification; FGFR = fibroblast growth factor receptor; Muc = mucinous adenocarcinoma; Pap = papillary adenocarcinoma; Por = poorly differentiated adenocarcinoma; pStage = pathological stage; Sig = signet ring-cell carcinoma; Tub = tubular adenocarcinoma. ^aComparison between pStage I-II and III+IV. ^bComparison between intestinal (Tub1, Tub2 and Pap) and others. P-values were calculated using the t-test for age and the χ^2 test for the other variables.




Figure 2 (A) Amplification of *FGFRs* in surgical specimens of gastric cancer. A TaqMan copy number assay for *FGFR2* was performed using DNA samples obtained from 267 FFPE samples. Human normal genomic DNA was used as a normal control. *FGFR2* amplification over 5 copies was observed in 11 cases (92.0, 63.0, 41.4, 19.9, 18.4, 13.7, 8.3, 6.2, 6.2, 5.7 and 5.6 copies). (B) Fluorescence *in situ* hybridisation analysis of *FGFR2*-amplified KATO-III cells, non-amplified OCUM1 cells and nine surgical specimens of gastric cancer. Green, signal of *CEN10P* locus; Red, signal of *FGFR2* locus; G3~G92, sample numbers; Amp, gene amplification. High-power images are presented for a single cancer cell. (C) Overall survival in *FGFR2*-amplified gastric cancer. Kaplan-Meier curves for OS according to the *FGFR2* amplification status.

Table 2 Summary of *FGFR2*-amplified gastric cancers

No.	Age	Sex	Location	Size of lesion (cm)	Macroscopic type ^a	Lauren's classification	Histology	pStage	OS (days)	FGFR2 (CN)	FISH (type, copies)
G7	55	M	Lower	8.5 × 8	3	Diffuse	Muc > Por2, Sig	IV	612	41.4	LC, +++
G38	70	M	Upper	8.5 × 8	1 + IIc	Intestinal	Pap > Tub1, Tub2, Por2	IIIa	591	92.0	MS, +++
G44	70	M	Lower	9.5 × 8	3	Diffuse	Por2 > Pap, Tub1, Muc	IIIa	938	5.6	Low, 2.2 ^b
G46	75	M	Middle	10 × 6	4	Intestinal	Tub2 > Por2	IV	2380	13.7	MS, +++
G92	75	M	Middle	6.5 × 5.5	3	Diffuse	Por2 > Tub2	IV	280	19.9	MS, +++
G154	59	M	Middle	14 × 12	4	Diffuse	Por2	IV	132	5.7	MS, +++
G163	64	M	Lower	15 × 10	3	Diffuse	Muc > Sig > Tub2	IV	540	6.2	LC, +++
G203	64	M	Lower	10.5 × 6.5	4	Diffuse	Sig > Por2 > Muc	IV	283	8.3	ND
G271	91	M	Upper	7 × 6.5	2	Intestinal	Tub2 > Por1	IV	383	63.0	ND
G299	65	M	Middle	20 × 20	4	Diffuse	Por2 > Sig	IV	256	6.2	ND
G329	67	M	Middle	6.5 × 6	3	Diffuse	Por2 > Sig	IIIa	3642+	18.4	ND

Abbreviations: CN = copy number of *FGFR2* determined using a copy number assay; Diffuse = diffuse-type gastric cancer; FISH = fluorescence *in situ* hybridisation; *FGFR2* = fibroblast growth factor receptor 2; Intestinal = intestinal-type gastric cancer; Location = tumor location in stomach; LC = large clustered signals; Low = low copy number gain; M = male; MS = multiple scattered signals; ND, not determined; No. = sample numbers; OS = overall survival; pStage = pathological stage; +++ = numerous *FGFR2* signals; + = patients. alive. ^aMacroscopic type, classification is based on the definitions of the Japanese Research Society for Gastric Cancer. ^bRatio of *FGFR2*/CEN10p.

histologies of two cases were intestinal-type gastric cancer and one was unclassified type, while the others were diffuse-type (Table 2). The tumours were located in either the upper or lower stomach. These results are summarised in Table 2. Finally, we examined the prognostic impact of *FGFR2* amplification on OS after surgery. *FGFR2* amplification tended to be associated with a poorer outcome, compared with non-amplified cases, but no significant difference was observed in the current study (log-rank test, *P* = 0.075; Figure 2C).

DISCUSSION

To date, several studies have reported on the protein expression of *FGFR2* and clinicopathological analyses using immunohistochemistry, with 20 of 49 (41%) and 42 of 134 (31%) gastric cancers expressing *FGFR2* protein when evaluated using positive or negative staining (Hattori *et al*, 1996; Toyokawa *et al*, 2009). Regarding genomic alteration, the frequency of *FGFR2* amplification has been reported to be 3 out of 19 (16%, among diffuse-type gastric cancers) detected using comparative genomic hybridisation (CGH), 3 out of 57 (5%) detected using Southern blot analysis, and 2 out of 30 (7%) detected using CGH (Tsujimoto *et al*, 1997; Peng *et al*, 2003; Kim *et al*, 2010). These results suggest that the frequency of *FGFR2* amplification is around 5%, which is lower than the positive staining results obtained using immunohistochemistry. However, the frequency of amplification has not been determined in a large cohort. Our results indicated that the frequency of *FGFR2* amplification was 4.1% (11 out of 267), consistent with these previous reports on genomic alterations. To select a sub-population of gastric cancers sensitive to *FGFR* inhibitors in the future, gene amplification may be a more suitable biomarker than positive staining using immunohistochemistry based on the results of preclinical studies (Figure 1, Takeda *et al*, 2007).

In six cases, the copy number of *FGFR2* was larger than 10 copies and numerous signals were observed by the FISH analysis (Figure 2B), indicating that these gastric cancer cells harboured high levels of amplification, similar to the results obtained using gastric cancer cell lines. Preclinical studies suggest that these cases may be likely to respond to *FGFR* inhibitors. In the remaining case, *FGFR2* amplification was relatively low (4~8 copies, G44). Such cases with low levels of *FGFR2* amplification may require further investigation regarding their sensitivity to *FGFR* inhibitors in the future. Meanwhile, we used a copy number assay to detect gene amplification in FFPE samples. Although DNA extracted from FFPE samples was considered to be of low quality with a DNA

degradation in general, a copy number assay was capable of detecting and screening amplification in the FFPE samples, which had been stored for as long as 10 years. The results were consistent with the results of FISH studies in several cell lines, with seven positive cases and two negative cases. Our findings suggest that a copy number assay is a powerful tool for detecting and screening gene amplification using FFPE samples.

Recently, trastuzumab in combination with chemotherapy has been regarded as a new standard option for patients with HER2-positive advanced gastric or gastro-oesophageal junction cancer (Bang *et al*, 2010). Therefore, the evaluation of both the HER2 and *FGFR2* status before anti-cancer treatment may be needed in gastric cancer patients in the near future. Many small molecules of *VEGFR2* tyrosine kinase inhibitors, categorised as anti-angiogenic agents, are now under clinical evaluation, and some of them, including sorafenib for hepatocellular carcinoma and sunitinib for renal cell carcinoma, are being clinically used as standard treatment options (Ellis and Hicklin, 2008). These compounds are also known to have a potential kinase inhibitory effect on *FGFRs* (Takeda *et al*, 2007; Turner *et al*, 2010), indicating that the development of these multi-kinase inhibitors may be a promising approach to the treatment of *FGFR2*-amplified gastric cancer. In addition to small molecular *FGFR* tyrosine kinase inhibitors, anti-*FGFR* antibodies, such as IMC-A1, PRO-001a and R3Mab, also offer promise as molecular-based drugs (Turner and Grose, 2010). We plan to conduct a prospective study in a cohort of Japanese patients with *FGFR2*-amplified gastric cancers.

In conclusion, we found that *FGFR2* amplification was observed in gastric cancer at a frequency of about 4.1%, and a copy number assay was a powerful tool for screening for *FGFR2* amplifications using FFPE samples. Our results warrant strong consideration of the development of *FGFR* inhibitors for the treatment of gastric cancers with *FGFR2* amplification.

ACKNOWLEDGEMENTS

We thank Miss Tomoko Kitayama and Miss Hideko Morita for their technical assistance. This study was supported by the Third-Term Comprehensive 10-Year Strategy for Cancer Control and a Grant-in-Aid for Cancer Research from the Ministry of Health, Labour and Welfare.

Conflict of interest

The authors declare no conflict of interest.

REFERENCES

- Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK (2010) Trastuzumab in combination with chemotherapy vs chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet* 376(9742): 687–697
- Beenken A, Mohammadi M (2009) The FGF family: biology, pathophysiology and therapy. *Nat Rev Drug Discov* 8(3): 235–253
- Bittoni A, Maccaroni E, Scartozzi M, Berardi R, Cascinu S (2010) Chemotherapy for locally advanced and metastatic gastric cancer: state of the art and future perspectives. *Eur Rev Med Pharmacol Sci* 14(4): 309–314
- Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau X, Chopin D, Thiery JP, Radvanyi F (1999) Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. *Nature Genet* 23: 18–20
- Courjal F, Cuny M, Simony-Lafontaine J, Louason G, Speiser P, Zeillinger R, Rodriguez C, Theillet C (1997) Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. *Cancer Res* 57: 4360–4367
- Dutt A, Salvesen HB, Chen TH, Ramos AH, Onofrio RC, Hatton C, Nicoletti R, Winckler W, Grewal R, Hanna M, Wyhs N, Ziaugra L, Richter DJ, Trovik J, Engelsen IB, Stefansson IM, Fennell T, Cibulskis K, Zody MC, Aklsen LA, Gabriel S, Wong KK, Sellers WR, Meyerson M, Greulich H (2008) Drug-sensitive FGFR2 mutations in endometrial carcinoma. *Proc Natl Acad Sci USA* 105: 8713–8717
- Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. *Nat Rev Cancer* 8(8): 579–591
- Fujii M, Kochi M, Takayama T (2010) Recent advances in chemotherapy for advanced gastric cancer in Japan. *Surg Today* 40(4): 295–300
- Giri D, Ropiquet F, Ittmann M (1999) Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. *Clin Cancer Res* 5: 1063–1071
- Grose R, Dickson C (2005) Fibroblast growth factor signaling in tumorigenesis. *Cytokine Growth Factor Rev* 16: 179–186
- Hattori Y, Itoh H, Uchino S, Hosokawa K, Ochiai A, Ino Y, Ishii H, Sakamoto H, Yamaguchi N, Yanagihara K, Hirohashi S, Sugimura T, Terada M (1996) Immunohistochemical detection of K-sam protein in stomach cancer. *Clin Cancer Res* 2: 1373–1381
- Hattori Y, Odagiri H, Nakatani H, Miyagawa K, Naito K, Sakamoto H, Katoh O, Yoshida T, Sugimura T, Terada M (1990) K-sam, an amplified gene in stomach cancer, is a member of the heparin-binding growth factor receptor genes. *Proc Natl Acad Sci USA* 87: 5983–5987
- Itoh H, Hattori Y, Sakamoto H, Ishii H, Kishi T, Sasaki H, Yoshida T, Koono M, Sugimura T, Terada M (1994) Preferential alternative splicing in cancer generates a K-sam messenger RNA with higher transforming activity. *Cancer Res* 54: 3237–3241
- Jang JH, Shin KH, Park JG (2001) Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. *Cancer Res* 61: 3541–3543
- Kaneda H, Arai T, Tanaka K, Tamura D, Aomatsu K, Kudo K, Sakai K, De Velasco MA, Matsumoto K, Fujita Y, Yamada Y, Tsurutani J, Okamoto I, Nakagawa K, Nishio K (2010) FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth. *Cancer Res* 70(5): 2053–2063
- Kim HK, Choi IJ, Kim CG, Kim HS, Oshima A, Yamada Y, Arai T, Nishio K, Michalowski A, Green JB (2010) Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy. *Pharmacogenomics J*; e-pub ahead of print 21 December 2010
- Matsumoto K, Arai T, Tanaka K, Kaneda H, Kudo K, Fujita Y, Tamura D, Aomatsu K, Tamura T, Yamada Y, Saijo N, Nishio K (2009) mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells. *Cancer Res* 69(18): 7160–7164
- Moffa AB, Tannheimer SL, Ethier SP (2004) Transforming potential of alternatively spliced variants of fibroblast growth factor receptor 2 in human mammary epithelial cells. *Mol Cancer Res* 2: 643–652
- Motoi T, Kumagai A, Tsuji K, Imamura T, Fukusato T (2010) Diagnostic utility of dual-color break-apart chromogenic *in situ* hybridization for the detection of rearranged SS18 in formalin-fixed, paraffin-embedded synovial sarcoma. *Hum Pathol* 41(10): 1397–1404
- Nakamura K, Yashiro M, Matsuoka T, Tendo M, Shimizu T, Miwa A, Hirakawa K (2006) A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, KI23057, for Scirrhous gastric cancer. *Gastroenterology* 131(5): 1530–1541
- Peng DF, Sugihara H, Mukaiho K, Tsubosa Y, Hattori T (2003) Alterations of chromosomal copy number during progression of diffuse-type gastric carcinomas: metaphase- and array-based comparative genomic hybridization analyses of multiple samples from individual tumours. *J Pathol* 201(3): 439–450
- Rand V, Huang J, Stockwell T, Ferriera S, Buzko O, Levy S, Busam D, Li K, Edwards JB, Eberhart C, Murphy KM, Tsiamouri A, Beeson K, Simpson AJ, Venter JC, Riggins GJ, Strausberg RL (2005) Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. *Proc Natl Acad Sci USA* 102: 14344–14349
- Takeda M, Arai T, Yokote H, Komatsu T, Yanagihara K, Sasaki H, Yamada Y, Tamura T, Fukuoka K, Kimura H, Saijo N, Nishio K (2007) AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor. *Clin Cancer Res* 13(10): 3051–3057
- Toyokawa T, Yashiro M, Hirakawa K (2009) Co-expression of keratinocyte growth factor and K-sam is an independent prognostic factor in gastric carcinoma. *Oncol Rep* 21(4): 875–880
- Tsujimoto H, Sugihara H, Hagiwara A, Hattori T (1997) Amplification of growth factor receptor genes and DNA ploidy pattern in the progression of gastric cancer. *Virchows Arch* 431(6): 383–389
- Turner N, Grose R (2010) Fibroblast growth factor signalling: from development to cancer. *Nat Rev Cancer* 10(2): 116–129
- Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, Natrajan R, Marchio C, Iorns E, Mackay A, Gillett C, Grigoriadis A, Tutt A, Reis-Filho JS, Ashworth A (2010) FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. *Cancer Res* 70(5): 2085–2094
- Ueda T, Sasaki H, Kuwahara Y, Nezu M, Shibuya T, Sakamoto H, Ishii H, Yanagihara K, Mafune K, Makuuchi M, Terada M (1999) Deletion of the carboxyl-terminal exons of K-sam/FGFR2 by short homology-mediated recombination, generating preferential expression of specific messenger RNAs. *Cancer Res* 59(24): 6080–6086

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.

First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer

Satoru Iwasa · Takako Eguchi Nakajima · Kenichi Nakamura · Atsuo Takashima · Ken Kato · Tetsuya Hamaguchi · Yasuhide Yamada · Yasuhiro Shimada

Received: 18 October 2010 / Accepted: 18 April 2011 / Published online: 15 May 2011
© The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2011

Abstract

Background Treatment with an oral fluoropyrimidine plus cisplatin is widely used for advanced gastric cancer, but patients with severe peritoneal metastasis often cannot tolerate such treatment, due to inadequate oral intake or massive ascites. The aim of this study was to assess the efficacy and safety of systemic chemotherapy for advanced gastric cancer with severe peritoneal metastasis.

Methods The cases of 92 patients with advanced gastric cancer and severe peritoneal metastasis who received first-line chemotherapy at our hospital between May 2001 and February 2007 were retrospectively analyzed. Severe peritoneal metastasis was defined as massive ascites or inadequate oral intake due to peritoneal dissemination. Inadequate oral intake was defined as having required an intravenous drip infusion.

Results All 92 patients received 5-fluorouracil (5-FU)-based chemotherapy; 40 of the patients had massive ascites, 34 had inadequate oral intake, and the remaining 18 had both conditions. Among the 86 patients having assessable ascites, 23 (27%) patients showed an improvement in ascites. Of the 52 patients with inadequate oral intake, 17 (33%) patients improved to the point of ingesting without intravenous drip infusion after receiving the chemotherapy. Median time to treatment failure and

overall survival time were 1.9 months [95% confidence interval (CI) 1.3–2.5 months] and 4.6 months (95% CI 3.9–5.3 months), respectively. Major grade 3 or 4 adverse events were anorexia (26%), neutropenia (26%), and anemia (22%).

Conclusion The treatment regimen of 5-FU-based chemotherapy for advanced gastric cancer with severe peritoneal metastasis was feasible, but its efficacy was not sufficient.

Keywords Gastric cancer · Peritoneal metastasis · Ascites · Oral intake

Introduction

Gastric cancer can spread through various routes, such as by local extension of direct serosal invasion, the lymphatic pathway, and the hematogenous route. Peritoneal metastasis can be disseminated from T3/T4 gastric cancer cells breaking through the serosa. Peritoneal metastasis is reported to be a common reason for the unresectability of gastric cancer [1], and it is also reported to be a common pattern of recurrence after curative resection [2–4]. Peritoneal metastasis causes serious clinical complications such as intestinal obstruction, massive ascites, and hydro-nephrosis. These complications are associated with abdominal pain, abdominal fullness, and vomiting, resulting in an extremely poor quality of life for the patients.

Recently, an oral fluoropyrimidine plus cisplatin regimen was demonstrated as a standard regimen against advanced gastric cancer in several large clinical Phase III trials [5–7]. However, in these trials, patients with severe peritoneal metastasis, such as those with massive ascites and intestinal obstruction, were excluded from the

S. Iwasa · T. E. Nakajima (✉) · K. Kato · T. Hamaguchi · Y. Yamada · Y. Shimada

Gastrointestinal Oncology Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
e-mail: tnakajima@marianna-u.ac.jp

K. Nakamura · A. Takashima
Clinical Trials and Practice Support Division, Center for Cancer Control and Information Services, National Cancer Center Hospital, Tokyo, Japan

eligibility criteria because they were unable to tolerate hydration, as required during cisplatin-containing chemotherapy, or continue to receive stable oral fluoropyrimidine chemotherapy.

We retrospectively investigated a regimen of chemotherapy, and its safety and efficacy for gastric cancer patients with severe peritoneal metastasis to determine the indications for chemotherapy and to consider the most suitable regimen.

Patients and methods

Patients

Patients who received first-line chemotherapy for gastric cancer at the National Cancer Center Hospital, Tokyo, between May 2001 and February 2007 were retrospectively recruited for this study according to the following criteria: histologically proven gastric adenocarcinoma; unresectable or recurrent disease; histologically or radiologically confirmed severe peritoneal metastasis; and no prior chemotherapy (adjuvant chemotherapy completed more than 6 months before recruitment was allowed) or radiotherapy. We defined severe peritoneal metastasis as massive ascites or inadequate oral intake due to peritoneal dissemination. We defined inadequate oral intake as requiring and actually receiving an intravenous drip infusion. Patients who were administered an intravenous drip infusion for the purpose of renal protection or as a drug administration route, such as for analgesics, were excluded.

Ascites was classified in four levels: none; mild; moderate; and massive. "None" was defined as undetected by computed tomography (CT) scan; "mild" ascites was localized in only one area such as the pelvic cavity or surface of the liver; "moderate" ascites did not correspond to either mild or massive ascites; and "massive" ascites extended throughout the abdominal cavity.

This retrospective study was approved by the Institutional Review Board of the National Cancer Center and was conducted in accordance with the ethical principles stated in Japan's Ethics Guidelines for Epidemiological Research.

Assessment of response and toxicity

Response in ascites was evaluated as follows: "disappearance" was defined as being undetected by CT scan, "decrease" was defined as decreasing by more than one level, "no change" was defined as remaining at the pre-treatment level, and "progression" was defined as deteriorating to a more severe level or becoming clinically worse with more frequently required drainage of ascites. We

evaluated the response rate in ascites without interval confirmation. Oral intake improvement was defined as maintaining an adequate amount of intake for 7 days or more without an intravenous drip infusion. Time to treatment failure (TTF) was defined as the interval between the start of treatment and the earliest date among disease progression (either radiologic or symptomatic progression), treatment discontinuation, or death due to any cause. Overall survival (OS) was measured from the start of treatment to the date of death or last follow-up. Survival curves were estimated using the Kaplan–Meier method. All statistical analyses were performed using Dr. SPSS II software (SPSS Japan, Tokyo, Japan). Toxicity was assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0.

Results

Patient characteristics

A total of 92 patients with severe peritoneal disseminated gastric cancer received systemic chemotherapy between May 2001 and February 2007. The patient characteristics are summarized in Table 1. About half of the patients had a baseline Eastern Cooperative Oncology Group performance status of 2 or greater.

Chemotherapy

All patients received 5-FU-based chemotherapy regimens. The regimens consisted of methotrexate (MTX)/5-FU in 64 patients, 5-FU continuous infusion (ci) in 21 patients, low-dose 5-FU in 6 patients, and 5-FU/l-leucovorin (l-LV) in 1 patient. The MTX/5-FU regimen consisted of a weekly MTX dose [100 mg/m², intravenously (iv)] followed by 5-FU (600 mg/m², iv) administered 3 h after the MTX infusion. Leucovorin rescue, 15 mg orally or intravenously every 6 h for 6 times, was started 24 h after the MTX infusion. Furthermore, leucovorin rescue was continued until the serum MTX concentration was less than 5×10^{-8} mol/L if physicians judged there to be a requirement for additional doses. The low-dose 5-FU regimen consisted of a daily infusion of 5-FU (300 mg/m²/day) [8], while 5-FU ci consisted of 800 mg/m²/day for 5 days every 4 weeks. The 5-FU/l-LV regimen consisted of weekly 5-FU (500 mg/m², iv) plus l-LV (200 mg/m², iv).

Efficacy

Among the 92 patients, 86 (93%) had mild or more severe ascites at initial diagnosis. The remaining 6 (7%) patients had intestinal stenosis without ascites. The response rate in